OncoD-F12

OncoD-F12 is an engineered oncolytic herpes simplex virus type 1 (oHSV-1) designed for the treatment of glioblastoma (GBM) and other solid tumors characterized by oncogenic Notch signaling. It is a second-generation vector derived from OncoD-F, modified to co-express the asparaginyl hydroxylase factor inhibiting HIF-1 (FIH1) and the immunoregulatory cytokine interleukin-12 (IL-12). FIH1 acts to locally and specifically downregulate Notch signaling, which is frequently upregulated in GBM and contributes to tumor progression and therapy resistance. The inclusion of IL-12 is intended to enhance the recruitment and cytotoxic activity of T cells within the tumor microenvironment, thereby boosting anti-tumor immunity. Preclinical studies in mouse models of GBM have demonstrated that OncoD-F12 can delay tumor growth and improve survival by reducing tumor-associated macrophages and enriching T cell populations.